Literature DB >> 31478910

Functional diversification of IgGs through Fc glycosylation.

Taia T Wang1,2, Jeffrey V Ravetch3.   

Abstract

IgG antibodies are secreted from B cells and bind to a variety of pathogens to control infections as well as contribute to inflammatory diseases. Many of the functions of IgGs are mediated through Fcγ receptors (FcγRs), which transduce interactions with immune complexes, leading to a variety of cellular outcomes depending on the FcγRs and cell types engaged. Which FcγRs and cell types will be engaged during an immune response depends on the structure of Fc domains within immune complexes that are formed when IgGs bind to cognate antigen(s). Recent studies have revealed an unexpected degree of structural variability in IgG Fc domains among people, driven primarily by differences in IgG subclasses and N-linked glycosylation of the CH2 domain. This translates, in turn, to functional immune diversification through type I and type II FcγR-mediated cellular functions. For example, Fc domain sialylation triggers conformational changes of IgG1 that enable interactions with type II FcγRs; these receptors mediate cellular functions including antiinflammatory activity or definition of thresholds for B cell selection based on B cell receptor affinity. Similarly, presence or absence of a core fucose alters type I FcγR binding of IgG1 by modulating the Fc's affinity for FcγRIIIa, thereby altering its proinflammatory activity. How heterogeneity in IgG Fc domains contributes to human immune diversity is now being elucidated, including impacts on vaccine responses and susceptibility to disease and its sequelae during infections. Here, we discuss how Fc structures arising from sialylation and fucosylation impact immunity, focusing on responses to vaccination and infection. We also review work defining individual differences in Fc glycosylation, regulation of Fc glycosylation, and clinical implications of these pathways.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31478910      PMCID: PMC6715372          DOI: 10.1172/JCI130029

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  86 in total

1.  DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells.

Authors:  T B Geijtenbeek; D S Kwon; R Torensma; S J van Vliet; G C van Duijnhoven; J Middel; I L Cornelissen; H S Nottet; V N KewalRamani; D R Littman; C G Figdor; Y van Kooyk
Journal:  Cell       Date:  2000-03-03       Impact factor: 41.582

2.  The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex.

Authors:  P Sondermann; R Huber; V Oosthuizen; U Jacob
Journal:  Nature       Date:  2000-07-20       Impact factor: 49.962

3.  Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell trans-infection.

Authors:  Franck Halary; Ali Amara; Hugues Lortat-Jacob; Martin Messerle; Thierry Delaunay; Corinne Houlès; Franck Fieschi; Fernando Arenzana-Seisdedos; Jean François Moreau; Julie Déchanet-Merville
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

4.  The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms.

Authors:  Y Mimura; S Church; R Ghirlando; P R Ashton; S Dong; M Goodall; J Lund; R Jefferis
Journal:  Mol Immunol       Date:  2000 Aug-Sep       Impact factor: 4.407

5.  High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

Authors:  R L Shields; A K Namenuk; K Hong; Y G Meng; J Rae; J Briggs; D Xie; J Lai; A Stadlen; B Li; J A Fox; L G Presta
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

6.  C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans.

Authors:  Carmen P Alvarez; Fátima Lasala; Jaime Carrillo; Oscar Muñiz; Angel L Corbí; Rafael Delgado
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

7.  Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

Authors:  R A Clynes; T L Towers; L G Presta; J V Ravetch
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

8.  Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding.

Authors:  Y Mimura; P Sondermann; R Ghirlando; J Lund; S P Young; M Goodall; R Jefferis
Journal:  J Biol Chem       Date:  2001-09-20       Impact factor: 5.157

9.  Dendritic cell (DC)-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin (DC-SIGN, CD209), a C-type surface lectin in human DCs, is a receptor for Leishmania amastigotes.

Authors:  María Colmenares; Amaya Puig-Kröger; Oscar Muñiz Pello; Angel L Corbí; Luis Rivas
Journal:  J Biol Chem       Date:  2002-07-16       Impact factor: 5.157

10.  The cell surface receptor DC-SIGN discriminates between Mycobacterium species through selective recognition of the mannose caps on lipoarabinomannan.

Authors:  Norihiro Maeda; Jérôme Nigou; Jean-Louis Herrmann; Mary Jackson; Ali Amara; Philippe Henri Lagrange; Germain Puzo; Brigitte Gicquel; Olivier Neyrolles
Journal:  J Biol Chem       Date:  2002-12-20       Impact factor: 5.157

View more
  35 in total

Review 1.  Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteins.

Authors:  Yukako Ohyama; Kazuki Nakajima; Matthew B Renfrow; Jan Novak; Kazuo Takahashi
Journal:  Expert Rev Proteomics       Date:  2020-05-28       Impact factor: 3.940

2.  Glycosylation of Antigen-Specific Antibodies: Perspectives on Immunoglobulin G Glycosylation in Vaccination and Immunotherapy.

Authors:  Pranay Bharadwaj; Margaret E Ackerman
Journal:  Exp Suppl       Date:  2021

Review 3.  Mechanisms of organ transplant injury mediated by B cells and antibodies: Implications for antibody-mediated rejection.

Authors:  Anita S Chong
Journal:  Am J Transplant       Date:  2020-06       Impact factor: 8.086

4.  Biological and structural characterization of murine TRALI antibody reveals increased Fc-mediated complement activation.

Authors:  Eveline A N Zeeuw van der Laan; Saskia van der Velden; Arthur E H Bentlage; Mads D Larsen; Thijs L J van Osch; Juk Yee Mok; Giso Brasser; Dionne M Geerdes; Carolien A M Koeleman; Jan Nouta; John W Semple; Leendert Porcelijn; Wim J E van Esch; Manfred Wuhrer; C Ellen van der Schoot; Gestur Vidarsson; Rick Kapur
Journal:  Blood Adv       Date:  2020-08-25

Review 5.  Tissues: the unexplored frontier of antibody mediated immunity.

Authors:  Nicholas E Webb; Biana Bernshtein; Galit Alter
Journal:  Curr Opin Virol       Date:  2021-02-10       Impact factor: 7.090

Review 6.  Glycosylation is a key in SARS-CoV-2 infection.

Authors:  Celso A Reis; Rudolf Tauber; Véronique Blanchard
Journal:  J Mol Med (Berl)       Date:  2021-05-22       Impact factor: 4.599

Review 7.  The landscape of bispecific T cell engager in cancer treatment.

Authors:  Shujie Zhou; Mingguo Liu; Fei Ren; Xiangjiao Meng; Jinming Yu
Journal:  Biomark Res       Date:  2021-05-26

Review 8.  Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.

Authors:  Cristina Capuano; Chiara Pighi; Simone Battella; Davide De Federicis; Ricciarda Galandrini; Gabriella Palmieri
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

9.  Expression and Functional Evaluation of Recombinant Anti-receptor Activator of Nuclear Factor Kappa-B Ligand Monoclonal Antibody Produced in Nicotiana benthamiana.

Authors:  Wanuttha Boonyayothin; Sirorut Sinnung; Balamurugan Shanmugaraj; Yoshito Abe; Richard Strasser; Prasit Pavasant; Waranyoo Phoolcharoen
Journal:  Front Plant Sci       Date:  2021-06-23       Impact factor: 5.753

10.  Changes of Serum IgG Glycosylation Patterns in Primary Biliary Cholangitis Patients.

Authors:  Xiaoli Zeng; Siting Li; Shiyi Tang; Xi Li; Guoyuan Zhang; Mengtao Li; Xiaofeng Zeng; Chaojun Hu
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.